Skip to main content

Advertisement

Log in

High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy

  • LUNG CANCER
  • Published:
Lung Aims and scope Submit manuscript

Abstract

Purpose

Systemic immune-inflammation index (SII) has been demonstrated to be closely associated with prognosis of a series of solid tumors. However, its role in small cell lung cancer (SCLC) remains poorly understood. The present study aims to evaluate the prognostic significance of pretreatment SII in SCLC treated with etoposide and platinum-based chemotherapy.

Methods

Sixty hundred and fifty-three newly diagnosed SCLC patients were enrolled. The optimal cut-off values for SII and LDH (lactate dehydrogenase) were obtained by a receiver operating characteristic (ROC) curve analysis. Overall survival (OS) was assessed by univariate and multivariate analyses.

Results

The optimal cut-off values of pretreatment SII and LDH were 748.51 × 109/L and 188.5 U/L, respectively. High pretreatment SII was significantly associated with advanced tumor stage (limited disease, LD vs. extensive disease, ED; 26.3% vs 46.5%; p < 0.001). On univariate analysis, age < 65 years, female, non-smoker, limited disease, SII < 748.51 × 109/L, LDH < 188.5 U/L, distant metastasis numbers < 2, chemotherapy + radiotherapy, and chemotherapy + surgery were closely correlated with a prolonged OS (p < 0.05). The median OS for patients in high SII group was 12.0 months, compared with that of 17.0 months for patients in low SII group. Multivariate analysis showed smoking history (p = 0.014), tumor stage (p < 0.001), pretreatment SII (p < 0.001), LDH (p = 0.002), distant metastasis numbers (p = 0.006), and chemotherapy + radiotherapy (p < 0.001) were independent prognostic factors of OS. Furthermore, SII remained prognostic significance for SCLC stratified by variable subgroups analysis.

Conclusion

Pretreatment SII represents a powerful prognostic biomarker for SCLC patients treated with etoposide and platinum-based chemotherapy. It is significant for treatment strategy making in clinics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gazdar AF, Bunn PA, Minna JD (2017) Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17(12):725–737

    Article  CAS  PubMed  Google Scholar 

  2. Rudin CM, Poirier JT (2017) Small-cell lung cancer in 2016: Shining light on novel targets and therapies. Nat Rev Clin Oncol 14(2):75–76

    Article  CAS  PubMed  Google Scholar 

  3. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Gao Y, Zhang H, Li Y, Wang D, Ma Y, Chen Q (2018) Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer. Clin Chim Acta 484:272–277

    Article  CAS  PubMed  Google Scholar 

  5. Tong YS, Tan J, Zhou XL, Song YQ, Song YJ (2017) Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med 15(1):221

    Article  PubMed Central  PubMed  Google Scholar 

  6. Chen L, Yan Y, Zhu L, Cong X, Li S, Song S et al (2017) Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Cancer Manage Res 9:849–867

    Article  CAS  Google Scholar 

  7. Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q (2015) Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 236(4):297–304

    Article  CAS  PubMed  Google Scholar 

  8. Tomita M, Ayabe T, Maeda R, Nakamura K (2018) Systemic immune-inflammation index predicts survival of patients after curative resection for non-small cell lung cancer. In Vivo 32(3):663–667

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Tomita M, Ayabe T, Maeda R, Nakamura K (2018) Comparison of inflammation-based prognostic scores in patients undergoing curative resection for non-small cell lung cancer. World J Oncol 9(3):85–90

    Article  PubMed Central  PubMed  Google Scholar 

  10. Wang D, Guo D, Shi F, Zhu Y, Li A, Kong L et al (2019) The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer. Future Oncol 15(29):3367–3379

    Article  CAS  PubMed  Google Scholar 

  11. Wang X, Jiang R, Li K (2014) Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem Biophys 69(3):633–640

    Article  CAS  PubMed  Google Scholar 

  12. Behera M, Ragin C, Kim S, Pillai RN, Chen Z, Steuer CE et al (2016) Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer 122(1):50–60

    Article  CAS  PubMed  Google Scholar 

  13. Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thromb Haemost 9(2):237–249

    Article  CAS  PubMed  Google Scholar 

  14. Lim JU, Yeo CD, Kang HS, Park CK, Kim JS, Kim JW et al (2018) Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. PLoS ONE 13(7):e0200341

    Article  PubMed Central  PubMed  Google Scholar 

  15. Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5):576–590

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE (2014) Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol 229(8):1005–1015

    Article  CAS  PubMed  Google Scholar 

  17. Jurasz P, AlonsoEscolano D, Radomski MW (2004) Platelet–cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 143(7):819–826

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Cao S, Jin S, Shen J, Cao J, Zhang H, Meng Q et al (2017) Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients. Oncotarget 8(5):8657–8669

    Article  PubMed  Google Scholar 

  19. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003) Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6(4):283–287

    Article  CAS  PubMed  Google Scholar 

  20. Shoji F, Morodomi Y, Akamine T, Takamori S, Katsura M, Takada K et al (2016) Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer. Lung Cancer 98:15–21

    Article  PubMed  Google Scholar 

  21. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2(11):850–861

    Article  CAS  PubMed  Google Scholar 

  22. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12(4):239–252

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Jin S, Cao S, Xu S, Wang C, Meng Q, Yu Y (2018) Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy. Clin Respir J 12(9):2433–2440

    Article  CAS  PubMed  Google Scholar 

  24. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol 31(7):860–867

    Article  CAS  PubMed  Google Scholar 

  25. Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA et al (2011) Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res 171(1):1–5

    Article  CAS  PubMed  Google Scholar 

  26. Fu Y, Chen SW, Chen SQ, Ou-Yang D, Liu WW, Song M et al (2016) A preoperative nutritional index for predicting cancer-specific and overall survival in chinese patients with laryngeal cancer: a retrospective study. Medicine 95(11):e2962

    Article  PubMed Central  PubMed  Google Scholar 

  27. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Can Res 58(16):3491–3494

    CAS  Google Scholar 

  28. Bernhardt D, Aufderstrasse S, Konig L, Adeberg S, Bozorgmehr F, Christopoulos P et al (2018) Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. Cancer Manage Res 10:6563–6569

    Article  CAS  Google Scholar 

  29. Wei XL, Zhang DS, He MM, Jin Y, Wang DS, Zhou YX et al (2016) The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. Tumour Biol 37(2):1879–1887

    Article  CAS  PubMed  Google Scholar 

  30. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 379(23):2220–2229

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was funded by Doctor’s Foundation of Linyi People’s Hospital (No 803) and National Natural Scientific Foundation of China (Grant No. 81673007).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shoubo Cao.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, C., Jin, S., Xu, S. et al. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy. Lung 198, 405–414 (2020). https://doi.org/10.1007/s00408-020-00333-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-020-00333-6

Keywords

Navigation